BI-1015550 is an inhibitor of PDE4 that displays anti-inflammatory activity. BI-1015550 has shown potential in the treatment of idiopathic pulmonary fibrosis and other fibro-proliferative diseases, producing promising results in clinical trials exploring the use of BI-1015550 as a treatment for idiopathic pulmonary fibrosis.

NX-2127 is a potent, selective, and orally bioavailable BTK degrader with Kd of 18 nM (for WT BTK), 45 nM (BTK C481S), 18 nM (BTK T474I), 44 nM (BTK M437R), 97 nM (BTK V416L), and 88 nM (BTK L528W), respectively. NX-2127 efficiently engages the intracellular ubiquitin-proteasome system to simultaneously bind both BTK and the CRBN E3 ubiquitin ligase complex, inducing polyubiquitination and proteasome-dependent degradation of BTK, IKZF1, and IKZF3.

MK-0616 is a potent, oral macrocyclic peptide inhibitor of PCSK9 that is not only able to reduce LDL-cholesterol, non-HDL-cholesterol, and apoB, but can also lower Lp(a).

BIOTIN-11-DCTP is a fluorescent dye for DNA labeling.

306-N16B is a lipidnanoparticle, and allows systemic codelivery of Cas9 mRNA and sgRNA. 306-N16B can transport mRNA to the pulmonaryendothelial cell. 306-N16B can be used for research of genome editing-based therapies. Based on the same lipid libraries with 306-O12B, the researchers also found that N-series ionizable lipids were able to selectively deliver mRNA to the lungs of mice. Compared with the liver-targeted O-series ionizable lipids which contained ester bond in lipid tail found in previous work, such as 306-O12B, the N-series ionizable lipids with the lipid tail containing amide bond prefer to deliver mRNA to the lung. As a N-series ionizable lipid, the chemical structure of the 306-N16B is shown in Figure 4a,b. The difference of organ targeting may be due to their adsorption of different protein coronas during blood circulation caused by their different structures mentioned earlier.It has shown that the second major protein of the protein corona adsorbed by liver-targeting 306-O12B iLNPs was apolipoprotein E (ApoE), while the three dominant proteins in the protein corona adsorbed by lung-targeting 306-N16B iLNPs were serum albumin, fibrinogen beta chain, and fibrinogen gamma chain. However, the 306-N16B iLNPs showed less organ selectivity when systematically codelivered Cas9 mRNA and sgRNA in vivo, which could simultaneously activate tdTomato expression in the liver and lung of Ai14 mice, whereas single mRNA delivery could almost exclusively deliver mRNA to the lungs. This surprising phenomenon requires further investigation. Both the change of iLNPs charge and the change of lipids functional group can influence the distribution of iLNPs in vivo due to the altering of protein corona composition. Therefore, it is possible to control the organ targeting of iLNPs by controlling the composition of the outer protein corona of iLNPs.

AA-T3A-C12 is an anisamide ligand-tethered lipidoid (AA-lipidoid) with high potency and selectivity to deliver RNA payloads to activated fibroblasts. HSP47 siRNA (siHSP47)-loaded AA-T3A-C12 LNP achieves ~65% knockdown and dramatically reduces liver fibrosis, which significantly outperforms the benchmark DLin-MC3-DMA (MC3) LNP.

ALC-0315 analogue-2 is an analogue of ALC-0315. ALC-0315 is an ionisable aminolipid that is responsible for mRNA compaction and aids mRNA cellular delivery and its cytoplasmic release through suspected endosomal destabilization. ALC-0315 can be used to form lipid nanoparticle (LNP) delivery vehicles. Lipid-Nanoparticles have been used in the research of mRNA COVID-19 vaccine.

Lipid 1 is an ionizable amino lipid used for the generation of Lipid nanoparticles (LNPs).

LNP Lipid-1 (Method B) is a lipid compound. LNP Lipid-1 is involved in the synthesis of lipid nanoparticles compositions. LNP Lipid-1 has potential applications in the transport of biologically active substances such as small molecule drugs, proteins, and nucleic acids.

Lipid 6 is an ionizable amino lipid used for the generation of Lipid nanoparticles .

A2-Iso5-4DC19 is a lipidoid compound. A2-Iso5-4DC19 is an effective carrier for the delivery of an agent such as a polynucleotide to a cell.

Lipid 15 is an ionizable amino lipid used for the generation of Lipid nanoparticles .

LNP Lipid-5 (Compound Lipid 2) is an ionizable lipid (amino lipid). LNP Lipid-5 can be used to prepare lipid nanoparticles .

244cis is a piperazine-based biodegradable ionizable lipid for LNP formulation. 244cis LNP has great potential for the treatment of chronic diseases in the lungs with improved potency and safety due to its low immunogenicity.

PSMA-1007 is a novel Glu-Ureido-type prostate-specific membrane antigen (PSMA) inhibitor.

DUPA(OtBu)-OH is a DUPA precursor. DUPA is used as the targeting moiety to actively deliver Docetaxel (DTX) for treatment of Prostate-Specific Membrane Antigen (PSMA) expressing prostate cancer.

Pentixafor is a ligand to make gallium Ga 68-pentixafor, a radioconjugate composed of a synthetic, cyclic pentapeptide analog of stromal-cell derived factor-1 (SDF-1 or CXCL12), which is a ligand for chemokine receptor C-X-C chemokine receptor type 4 (CXCR4), that is radiolabeled, via the macrocyclic chelating agent dodecanetetraacetic acid (DOTA), with the radioisotope gallium Ga 68 (Ga68; 68Ga), with potential use for imaging CXCR4-expressing cells upon positron emission tomography (PET)/computed tomography (CT). Upon administration of 68Ga-pentixafor, the pentixafor moiety targets and binds to CXCR4-expressing cancer cells. Upon PET/CT, CXCR4-expressing cancer cells can be visualized and the expression status of the receptor can be assessed. CXCR4, a marker of poorly differentiated cells, is overexpressed on various cancer cells, and plays a key role in tumor growth, progression, invasiveness and metastasi

R6 is a new ionizable lipid driven from AI-Guided Ionizable Lipid Engineering (AGILE) platform for mRNA delivery. R6 LNPs exhibits a 5-fold increase in transfection potency in RAW 264.7 and shows its potential to be utilized for the development of non-viral mRNA delivery vectors for immune cells.

H9 is a new ionizable lipid driven from AI-Guided Ionizable Lipid Engineering (AGILE) platform for mRNA delivery. H9 LNPs shows superior mRNA transfection potency compared to LNPs containing (D-Lin-MC3-DMA).

UAMC1110-NH2 (NH2-UAMC1110)is a derivative of UAMC1110 with a aminobutoxy group, which is useful to synthesie UAMC1110 conjugate. UAMC-1110, also known as SP-13786, is a novel potent and selective inhibitor of fibroblast activation protein (fap), displaying low nanomolar inhibitory potency and high selectivity against the related dipeptidyl peptidases (dpps) dppiv, dpp9, dppii, and prolyl oligopeptidase (prep).

[18F]PSMA-1007, a positron emission tomography (PET) tracer, specifically targets prostate-specific membrane antigen (PSMA), which is highly expressed in prostate cancer. PSMA-PET is effective especially for regional detection of biochemical recurrence, which significantly affects patient management. Herein, we established and optimized a one-step radiolabeling protocol to separate and purify [18F]PSMA-1007 with a CFN-MPS200 synthesizer for clinical application.